nivolumab,tegafur,oxaliplatin,oteracil,gimeracil,capecitabine
ono pharma,nordic group,otsuka,bms
['nivo', 'nivolumab', 'attraction-5', 'gi ']
first major gi trial results from #asco23. attraction-5 shows lack of efficacy of adding nivolumab to adjuvant chemo after at least d2 resection. well done trial on 1st glance with os data presented. negative trials as important as positive. 
Personal account. Med Onc. Associate Prof. @queensoncology @QueensuPHS. #cancerpolicy #cancergroundshot. Pubs: https://t.co/FTRPKNykq3 Talks- https://t.co/anav3AIZjO